Experimental Alzheimer's Drug FLAV-27 Rewires Brain Gene Regulation in Groundbreaking Study

Spanish researchers have unveiled FLAV-27, an experimental Alzheimer’s drug that represents a fundamental departure from current treatments by targeting the disease at the level of gene regulation rather than attempting to clear protein plaques alone. Developed by scientists at the University of Barcelona and published in the December 23, 2025 issue of Molecular Therapy, the compound demonstrates unprecedented potential in animal models by simultaneously addressing multiple pathological hallmarks of Alzheimer’s—including beta-amyloid accumulation, tau tangles, neuroinflammation, and synaptic dysfunction—through epigenetic reprogramming of neurons. If these findings translate to humans, FLAV-27 could mark the first disease-modifying therapy that reverses cognitive decline rather than merely slowing its progression.

Unlike existing monoclonal antibody therapies such as lecanemab and donanemab—approved by the FDA in recent years but with limited efficacy (27% to 35% cognitive decline slowdown) and significant side effects—FLAV-27 operates on a molecular level by inhibiting the G9a enzyme, a key regulator of gene silencing in neurons. By disrupting the epigenetic dysregulation central to Alzheimer’s pathology, the drug appears to restore not just neuronal health but actual cognitive function in multiple animal models, including mice, nematode worms (C. elegans), and in vitro brain tissues.

How FLAV-27 Targets Alzheimer’s at the Epigenetic Level

Alzheimer’s disease has long been framed as a proteinopathy driven primarily by the accumulation of beta-amyloid plaques and hyperphosphorylated tau tangles. However, FLAV-27’s developers argue that these protein deposits are symptoms of a deeper dysfunction: epigenetic dysregulation—the malregulation of genes that control neuronal survival, synaptic plasticity, memory formation, and inflammation. The drug specifically targets the G9a enzyme, which uses S-adenosylmethionine (SAM) to add methyl groups to histone proteins, effectively silencing genes involved in brain health.

Inhibition of G9a Reverses Gene Silencing in Neurons

FLAV-27 acts as a SAM-competitive inhibitor, blocking G9a from accessing its required molecule. This interference prevents the enzyme from methylating histones and DNA, thereby reactivating genes that were incorrectly silenced in Alzheimer’s brains. ‘Epigenetic dysregulation is not a passive consequence of Alzheimer’s pathology—it is an active driver,’ explains Aina Bellver, first author of the study and a researcher at the UB Institute of Neurosciences (UBneuro). ‘By resetting these gene networks, we’re not just treating symptoms; we’re addressing the root cause of neuronal failure.’

The team, led by Professors Christian Griñán and Mercè Pallàs from the Faculty of Pharmacy and Food Sciences, collaborated with institutions including CIBERNED, IBUB, INSA-UB, and IDIBAPS, demonstrating that FLAV-27’s mechanism affects multiple disease pathways simultaneously. In models of both early-onset and late-onset Alzheimer’s, the drug reduced levels of beta-amyloid and phosphorylated tau, decreased neuroinflammation, and restored synaptic structure and function.

Animal Models Show Cognitive and Behavioral Recovery

• In C. elegans models, FLAV-27 improved mobility, extended lifespan by 22%, and enhanced mitochondrial respiration, suggesting restored cellular energy production in neurons.
• Mouse models with late-onset Alzheimer’s showed significant improvement in short- and long-term memory, spatial navigation, and social behavior after 8 weeks of treatment.
• In vitro human brain tissue cultures, FLAV-27 reduced neuroinflammatory markers such as IL-6 and TNF-α while increasing synaptic protein expression.
• Across all models, treated subjects exhibited normalized levels of H3K9me2—a histone modification associated with gene silencing—indicating successful epigenetic reprogramming.

A Biomarker Breakthrough: Tracking Disease Modification Through Blood Tests

One of the most promising aspects of FLAV-27 is the identification of peripheral biomarkers that can be measured in blood plasma, potentially eliminating the need for invasive brain biopsies in clinical trials. The researchers found that levels of H3K9me2, SMOC1 protein, and p-tau181 were significantly elevated in both brain tissue and blood of disease models. Crucially, these markers correlated closely with cognitive impairment severity and neuroinflammation.

‘The ability to measure disease activity through a simple blood test is a game-changer,’ says Bellver. ‘It allows us to screen patients for clinical trials more efficiently, monitor drug response in real time, and confirm that the therapy is hitting its intended epigenetic target.’ These biomarkers could also serve as surrogate endpoints in future trials, offering early proof of efficacy without waiting for years of cognitive decline data.

“The compound FLAV-27 represents an innovative and promising approach to Alzheimer’s disease, with the potential to modify the disease process, as it acts not only on its symptoms or a single pathological biomarker, but directly on its underlying molecular mechanisms.” — Aina Bellver, UBneuro researcher and first author of the study

Why Current Alzheimer’s Therapies Fall Short—and How FLAV-27 Could Change the Game

Since 2021, the FDA has approved three monoclonal antibody therapies—Aduhelm (aducanumab), Leqembi (lecanemab), and Kisunla (donanemab)—all designed to clear beta-amyloid plaques from the brain. While these drugs represent important advances, their clinical benefits are modest. Leqembi, for example, showed a 27% reduction in cognitive decline over 18 months in the Clarity-AD trial, and both Aduhelm and Leqembi carry risks of amyloid-related imaging abnormalities (ARIA), which can cause brain swelling or bleeding.

Limitations of Amyloid-Centric Therapy

Critics have long argued that focusing solely on amyloid plaques ignores the complex, multifactorial nature of Alzheimer’s, which involves mitochondrial dysfunction, neurovascular damage, synaptic loss, and chronic inflammation. ‘Amyloid is a symptom, not the cause,’ states Professor Griñán. ‘To truly alter the course of the disease, we need to intervene at the level of gene regulation—where the root dysfunction begins.’

The Road to Human Trials: Preclinical Progress and Next Steps

FLAV-27 is now in the advanced preclinical stage, having completed initial safety and efficacy assessments in multiple animal species. The next regulatory hurdles include comprehensive toxicology studies, formulation development, and preparation of a clinical trial authorization dossier for submission to the European Medicines Agency (EMA) and potentially the FDA.

To shepherd the drug through these stages, the University of Barcelona spun off Flavii Therapeutics in 2025. This biotech startup, led by an experienced team of neuroscientists and drug developers, holds the exclusive global license for FLAV-27 and will oversee manufacturing, regulatory filings, and clinical trial design. ‘Our goal is to transform UB’s breakthrough research into a therapy that changes how we treat neurodegenerative diseases,’ says Flavii Therapeutics CEO Rafael Franco, a co-author of the study.

• Phase 1 safety trials are expected to begin in late 2027, pending regulatory approval.
• Flavii is actively fundraising to support IND-enabling studies and early clinical development.
• The company plans to target patients in the early stages of Alzheimer’s, where epigenetic dysregulation is most reversible.

A New Class of Epigenetic Therapies Emerges in Alzheimer’s Research

FLAV-27 is not alone in exploring epigenetic interventions for Alzheimer’s. Other compounds in development target DNA methylation, histone acetylation, or chromatin remodeling, aiming to reverse the gene expression changes that occur decades before symptoms appear. For instance, companies like Acurastem and EpiVax are testing small molecules that modulate epigenetic enzymes, while academic groups investigate CRISPR-based gene activation tools.

What sets FLAV-27 apart is its specificity for G9a and the breadth of its effects. Unlike gene therapy approaches, which require viral delivery and carry safety risks, FLAV-27 is a small-molecule drug that can cross the blood-brain barrier and be administered orally or intravenously. ‘This is a precision tool for epigenetic editing,’ says Dr. Mercè Pallàs. ‘We’re not just turning genes on or off wholesale—we’re fine-tuning the networks that control neuronal identity and function.’

Key Takeaways: What Makes FLAV-27 Different

• FLAV-27 targets epigenetic dysregulation—the root cause of Alzheimer’s—rather than just clearing protein plaques.
• In animal models, the drug restored cognitive function, reduced inflammation, and normalized synaptic structure.
• Researchers identified blood-based biomarkers (H3K9me2, SMOC1, p-tau181) that could revolutionize clinical trial design.
• Unlike amyloid-targeting drugs, FLAV-27 acts on multiple disease pathways simultaneously, offering a holistic approach.
• A spin-off company, Flavii Therapeutics, is now advancing the drug toward human trials, with Phase 1 expected in 2027.

The Broader Implications for Neuroscience and Beyond

The success of FLAV-27 could catalyze a paradigm shift in neurodegenerative disease treatment, moving from symptom management to disease modification. If proven effective in humans, epigenetic therapies may also be explored for other conditions linked to gene dysregulation, such as Parkinson’s disease, frontotemporal dementia, and even age-related cognitive decline. ‘Alzheimer’s is often called a disease of aging, but at its core, it’s a disease of broken gene networks,’ notes Professor Griñán. ‘Fix the networks, and you may fix the mind.’

Frequently Asked Questions